Nancy K Janz1, Yun Li2, Lauren J Beesley2, Lauren P Wallner3, Ann S Hamilton4, Rebecca A Morrison3, Sarah T Hawley3,5. 1. Department of Health Behavior and Health Education, School of Public Health, University of Michigan, 1415 Washington Heights, Ann Arbor, MI, 48109-2029, USA. nkjanz@umich.edu. 2. Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA. 3. University of Michigan Medical School, Ann Arbor, MI, USA. 4. Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. 5. Ann Arbor VA Medical Center, Ann Arbor, MI, USA.
Abstract
PURPOSE: The objectives of this study are to describe racial/ethnic differences and clinical/treatment correlates of worry about recurrence and examine modifiable factors in the health care experience to reduce worry among breast cancer survivors, partners, and pairs. METHODS: Women with non-metastatic breast cancer identified by the Detroit and Los Angeles SEER registries between 6/05 and 2/07 were surveyed at 9 months and 4 years. Latina and Black women were oversampled. Partners were surveyed at time 2. Worry about recurrence was regressed on sociodemographics, clinical/treatment, and modifiable factors (e.g., emotional support received by providers) among survivors, partners, and pairs. RESULTS: The final sample included 510 pairs. Partners reported more worry about recurrence than survivors. Compared to Whites, Latinas(os) were more likely to report worry and Blacks were less likely to report worry (all p < 0.05). Partners of survivors who received chemotherapy reported more worry (OR = 2.47 [1.45, 4.22]). Among modifiable factors, survivors and pairs who received more emotional support from providers were less likely to report worry than those survivors and pairs who did not receive such support (OR = 0.56 [0.32, 0.97]) and (OR = 0.45 [0.23,0.85]), respectively. CONCLUSIONS: Early identification of survivors and partners who are reporting considerable worry about recurrence can lead to targeted culturally sensitive interventions to avoid poorer outcomes. Interventions focused on health care providers offering information on risk and emotional support to survivors and partners is warranted.
PURPOSE: The objectives of this study are to describe racial/ethnic differences and clinical/treatment correlates of worry about recurrence and examine modifiable factors in the health care experience to reduce worry among breast cancer survivors, partners, and pairs. METHODS:Women with non-metastatic breast cancer identified by the Detroit and Los Angeles SEER registries between 6/05 and 2/07 were surveyed at 9 months and 4 years. Latina and Black women were oversampled. Partners were surveyed at time 2. Worry about recurrence was regressed on sociodemographics, clinical/treatment, and modifiable factors (e.g., emotional support received by providers) among survivors, partners, and pairs. RESULTS: The final sample included 510 pairs. Partners reported more worry about recurrence than survivors. Compared to Whites, Latinas(os) were more likely to report worry and Blacks were less likely to report worry (all p < 0.05). Partners of survivors who received chemotherapy reported more worry (OR = 2.47 [1.45, 4.22]). Among modifiable factors, survivors and pairs who received more emotional support from providers were less likely to report worry than those survivors and pairs who did not receive such support (OR = 0.56 [0.32, 0.97]) and (OR = 0.45 [0.23,0.85]), respectively. CONCLUSIONS: Early identification of survivors and partners who are reporting considerable worry about recurrence can lead to targeted culturally sensitive interventions to avoid poorer outcomes. Interventions focused on health care providers offering information on risk and emotional support to survivors and partners is warranted.
Entities:
Keywords:
Breast cancer; Survivors and partners; Worry about recurrence
Authors: Laurel L Northouse; Maria C Katapodi; Lixin Song; Lingling Zhang; Darlene W Mood Journal: CA Cancer J Clin Date: 2010-08-13 Impact factor: 508.702
Authors: Maria Papaleontiou; David Reyes-Gastelum; Brittany L Gay; Kevin C Ward; Ann S Hamilton; Sarah T Hawley; Megan R Haymart Journal: Thyroid Date: 2019-07-25 Impact factor: 6.568
Authors: Steven C Palmer; Carrie T Stricker; Angela M DeMichele; Marilyn Schapira; Karen Glanz; Jennifer J Griggs; Linda A Jacobs Journal: Support Care Cancer Date: 2017-02-23 Impact factor: 3.603
Authors: Nina Jackson Levin; Anao Zhang; David Reyes-Gastelum; Debbie W Chen; Ann S Hamilton; Bradley Zebrack; Megan R Haymart Journal: J Cancer Surviv Date: 2021-10-11 Impact factor: 4.062
Authors: Claire Kim; Laurel Liang; Frances C Wright; Nicole J Look Hong; Gary Groot; Lucy Helyer; Pamela Meiers; May Lynn Quan; Robin Urquhart; Rebecca Warburton; Anna R Gagliardi Journal: Breast Cancer Res Treat Date: 2017-12-23 Impact factor: 4.872
Authors: Young-Rock Hong; Sandhya Yadav; Ryan Suk; Ahmad Khanijahani; Daniel Erim; Kea Turner Journal: Cancer Med Date: 2021-05-07 Impact factor: 4.452
Authors: Kristen J Wells; Julia H Drizin; Amy E Ustjanauskas; Coralia Vázquez-Otero; Tonya M Pan-Weisz; Danielle Ung; Claudia Carrizosa; Christine Laronga; Richard G Roetzheim; Kenneth Johnson; Marilyn Norton; Rosa Cobian Aguilar; Gwendolyn P Quinn Journal: Support Care Cancer Date: 2021-07-07 Impact factor: 3.603
Authors: Nancy K Janz; Yun Li; Brian J Zikmund-Fisher; Reshma Jagsi; Allison W Kurian; Lawrence C An; M Chandler McLeod; Kamaria L Lee; Steven J Katz; Sarah T Hawley Journal: Breast Cancer Res Treat Date: 2016-12-09 Impact factor: 4.624
Authors: Debbie W Chen; David Reyes-Gastelum; Lauren P Wallner; Maria Papaleontiou; Ann S Hamilton; Kevin C Ward; Sarah T Hawley; Brian J Zikmund-Fisher; Megan R Haymart Journal: Cancer Date: 2019-12-23 Impact factor: 6.921